P. D. De Mulder

发表

Novel treatments for metastatic renal cell carcinoma.

D. V. van Spronsen, P. Mulders, P. D. De Mulder, 2005, Critical reviews in oncology/hematology.

Adherence to the guidelines of the CCCE in the treatment of node-positive breast cancer patients.

R. Grol, L. Beex, P. D. De Mulder, 2004, European journal of cancer.

Novel treatment strategies in clear-cell metastatic renal cell carcinoma.

D. V. van Spronsen, P. Mulders, P. D. De Mulder, 2005, Anti-cancer drugs.

Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party.

L. Collette, S. Fosså, R. Sylvester, 1999, Journal of the National Cancer Institute.

Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma

V. Tjan-Heijnen, M. Koopman, P. D. De Mulder, 2009, Acta oncologica.

E‐cadherin expression in head and neck squamous‐cell carcinoma is associated with clinical outcome

D. Ruiter, P. D. De Mulder, J. Manni, 1993, International journal of cancer.

Mitozolomide in advanced renal cancer. A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.

S. Fosså, R. Sylvester, A. V. van Oosterom, 1989, European journal of cancer & clinical oncology.

Cardiotoxicity as a dose‐limiting factor in a schedule of high dose bolus therapy with interleukin‐2 and alpha‐interferon. An unexpectedly frequent complication

P. D. De Mulder, S. Henzen‐Logmans, D. V. van Hoogenhuyze, 1994, Cancer.

Current treatment of renal cell carcinoma.

P. Mulders, P. D. De Mulder, C. V. van Herpen, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982).

D. Lacombe, J. Bogaerts, J. Bernier, 2008, European journal of cancer.

Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck.

J. Verweij, P. D. De Mulder, A. de Graeff, 1997, European journal of cancer.

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.

A. Eggermont, P. D. De Mulder, J. Gratama, 1996, British Journal of Cancer.

High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group.

M. van Glabbeke, S. Fosså, M. Glabbeke, 1995, European journal of cancer.

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

L. Collette, J. Witjes, C. Sternberg, 2006, European journal of cancer.

Intratumoral Administration of Recombinant Human Interleukin 12 in Head and Neck Squamous Cell Carcinoma Patients Elicits a T-Helper 1 Profile in the Locoregional Lymph Nodes

P. D. de Wilde, M. Looman, G. Adema, 2004, Clinical Cancer Research.

Effects of quality of treatment on prognosis in primary breast cancer patients treated in daily practice.

R. Grol, L. Beex, P. D. De Mulder, 2002, Anticancer research.

Quality assurance in medical oncology within the EORTC. European Organisation for Research and Treatment of Cancer.

P. Therasse, P. D. De Mulder, 2002, European journal of cancer.

Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.

W. Oyen, P. D. De Mulder, E. Oosterwijk, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.

J. Verweij, P. D. De Mulder, W. Oster, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Hypothyroidism and goiter in a patient during treatment with interleukin‐2

P. D. De Mulder, F. Corstens, C. Franks, 1990, Cancer.

HLA antigen expression in routinely processed head and neck squamous cell carcinoma primary lesions of different sites

D. Ruiter, P. D. De Mulder, J. Manni, 1991, International journal of cancer. Supplement = Journal international du cancer. Supplement.

Intratumoral PEG-interleukin-2 therapy in patients with locoregionally recurrent head and neck squamous-cell carcinoma.

P. van den Broek, D. Ruiter, P. D. De Mulder, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.

S. Fosså, S. Culine, A. Horwich, 2008, European urology.

Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

R. Millikan, C. Sternberg, J. Bellmunt, 2007, Urology.

The role of neoadjuvant or adjuvant chemotherapy for invasive bladder cancer Is there a benefit for survival or preserving the bladder?

W. Shipley, N. Miyanaga, S. Kamidono, 1998, Urologic oncology.

Extrapulmonary sarcoidosis primarily presenting as cholestatic liver disease

P. D. De Mulder, A. Hoorens, B. Maertens, 2019, BMJ Case Reports.

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.

P. D. De Mulder, G. Vreugdenhil, C. Punt, 1997, British Journal of Cancer.

A phase II study of sequential recombinant interleukin-2 followed by dacarbazine in metastatic melanoma.

D. Hossfeld, W. Fiedler, P. D. De Mulder, 1992, European journal of cancer.

Cytokines and soluble cytokine receptor induction after IL‐12 administration in cancer patients

E. Tartour, W. Fridman, P. D. De Mulder, 2000, Clinical and experimental immunology.

Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.

J. Verweij, C. Punt, A. Sparreboom, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of intermediate‐prognosis germ‐cell cancer: Results of a phase I/II study of Taxol‐BEP

S. Rodenhuis, J. Verweij, J. Schornagel, 1999, International journal of cancer.

A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission.

S. Rodenhuis, H. Keizer, E. de Vries, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.

L. Collette, S. Fosså, S. Kaye, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20).

L. Collette, S. Fosså, N. Aaronson, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.

R. Sylvester, S. Kaye, P. D. De Mulder, 1995, British Journal of Cancer.

The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma.

S. Kaye, P. D. De Mulder, G. Stoter, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.

D. Dearnaley, A. Horwich, R. Sylvester, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Polymorphism in the Splice Donor Site of ZNF419 Results in the Novel Renal Cell Carcinoma-Associated Minor Histocompatibility Antigen ZAPHIR

M. Kester, M. Griffioen, P. D. De Mulder, 2011, PloS one.

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

C. Seynaeve, J. Verweij, P. D. De Mulder, 1990, Annals of internal medicine.

Ondansetron in the prophylaxis of nausea and vomiting induced by cisplatin.

S. Kaasa, C. Seynaeve, J. Verweij, 1990, European Journal of Cancer.

The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting.

F. Debruyne, L. Beex, P. D. De Mulder, 1988, European journal of cancer & clinical oncology.

Re: p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy.

P. Span, F. Sweep, P. D. De Mulder, 2007, Journal of the National Cancer Institute.

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

A. V. van Oosterom, E. Voest, B. Hecquet, 1997, British Journal of Cancer.

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.

R. Sylvester, A. V. van Oosterom, P. D. De Mulder, 1995, British Journal of Cancer.

Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells.

M. Looman, G. Adema, P. D. De Mulder, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Continuous infusion of high‐dose 5‐fluorouracil in combination with leucovorin and recombinant interferon‐alpha‐2b in patients with advanced colorectal cancer. A multicenter phase II study

C. Punt, P. D. De Mulder, J. Burghouts, 1993, Cancer.

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.

L. Collette, R. Sylvester, A. V. van Oosterom, 1998, British Journal of Cancer.

Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.

R. Sylvester, A. V. van Oosterom, S. Kaye, 1997, British Journal of Cancer.

An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma.

A. V. van Oosterom, P. D. De Mulder, R. de Wit, 1997, European journal of cancer.

Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study.

J. Castelijns, J. Kaanders, A. Awada, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

From chemoprevention and organ preservation programmes to postoperative management: major achievements and strategies of the EORTC Head and Neck Cancer Group.

J. Bernier, C. Debruyne, H. Langendijk, 2012, European journal of cancer.

Delayed emesis following anticancer chemotherapy

M. Kris, F. Roila, P. D. De Mulder, 1998, Supportive Care in Cancer.

Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group.

R. Paridaens, J. Wanders, A. V. van Oosterom, 1994, European journal of cancer.

Polyethylene‐glycol‐modified interleukin‐2 is superior to interleukin‐2 in locoregional immunotherapy of established guinea‐pig tumors

P. D. De Mulder, P. Steerenberg, V. Mattijssen, 1992, International journal of cancer.

Treatment in germ cell tumours: state of the art.

P. D. De Mulder, R. de Wit, G. Oosterhof, 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC).

C. Baum, C. Peschel, N. Vogelzang, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2.

P. D. De Mulder, L. Massuger, J. V. D. van der Meer, 1993, Journal of the National Cancer Institute.

PEG‐IL‐2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclopphosphamide

P. D. De Mulder, R. Scheper, P. Steerenberg, 1994, International journal of cancer.

Epidural administration of morphine for control of cancer pain: long-term efficacy and complications.

T. Wobbes, P. D. De Mulder, J. Driessen, 1989, The Clinical Journal of Pain.

An uncommon cause of sciatic pain: tuberculous osteomyelitis of the ischial tuberosity

P. D. De Mulder, N. Baelde, T. De Bo, 2017, Acta clinica Belgica.

Metastatic breast cancer presenting as fever, rash, and arthritis

J. Drenth, P. D. De Mulder, J. V. D. van der Meer, 1995, Cancer.

European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).

W. Siegert, S. Fosså, S. Culine, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[Presence of the cestode Raillietina (R.) celebensis (Janicki, 1902) in a child from Tahiti].

P. D. De Mulder, A. Fain, P. Limbos, 1977, Annales de la Societe belge de medecine tropicale.

Human coccidiosis caused by Isospora belli. A second case observed in Belgium.

P. D. De Mulder, A. Fain, P. Limbos, 1965, Tropical and geographical medicine.

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

S. Fosså, S. Culine, A. Horwich, 2008, European urology.

Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.

W. Oyen, P. D. De Mulder, E. Oosterwijk, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S. Fosså, D. Dearnaley, A. Horwich, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma.

J. Klijn, J. Verweij, J. Schornagel, 1989, Journal of Urology.

Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group.

S. Rodenhuis, G. Snow, J. Verweij, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).

S. Fosså, R. Sylvester, A. V. van Oosterom, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intratumoral rhIL‐12 administration in head and neck squamous cell carcinoma patients induces B cell activation

J. A. van der Laak, G. Adema, P. D. De Mulder, 2008, International journal of cancer.

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group.

J. Verweij, J. Schornagel, F. Cognetti, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients

P. D. De Mulder, B. D. de Pauw, C. Verhagen, 1987, Antimicrobial Agents and Chemotherapy.

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer

L. Collette, C. Sternberg, J. Schornagel, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial.

E. D. de Vries, P. D. De Mulder, H. Sauerwein, 1996, British Journal of Cancer.

Immunotherapy for renal cell carcinoma.

Egbert Oosterwijk, P. D. De Mulder, E. Oosterwijk, 2003, European urology.

Vaccination of Patients With Metastatic Renal Cell Carcinoma With Autologous Dendritic Cells Pulsed With Autologous Tumor Antigens in Combination With Interleukin-2: A Phase 1 Study

F. Debruyne, W. Jongmans, G. Adema, 2002, Journal of immunotherapy.

Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC).

C. Sternberg, S. Kaye, P. D. De Mulder, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.

A. Graeff, J. Verweij, J. Schornagel, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients.

C. Lamers, P. Mulders, P. D. De Mulder, 2003, Folia biologica.

Establishing the role of cytokine therapy in advanced renal cell carcinoma

M. Gore, P. D. De Mulder, 2008, BJU international.

Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained.

J. Verweij, P. D. De Mulder, P. Schmitz, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic Response

W. Oyen, P. D. De Mulder, E. Oosterwijk, 2005, Clinical Cancer Research.

Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.

W. Oyen, J. Witjes, F. Debruyne, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy.

C. Seynaeve, J. Verweij, P. D. De Mulder, 1991, Clinical oncology (Royal College of Radiologists (Great Britain)).

Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II Study.

P. D. De Mulder, T. Oliver, H. Kirchner, 2009, Cancer biotherapy.

Intratumoral Recombinant Human Interleukin-12 Administration in Head and Neck Squamous Cell Carcinoma Patients Modifies Locoregional Lymph Node Architecture and Induces Natural Killer Cell Infiltration in the Primary Tumor

J. A. van der Laak, P. D. de Wilde, G. Adema, 2005, Clinical Cancer Research.

Interferons in renal-cell carcinoma: status and prospects.

F. Debruyne, P. D. De Mulder, A. Beniers, 1990, Progress in clinical and biological research.

Cisplatin‐based chemotherapy in advanced adenoid cystic carcinoma of the head and neck

J. Verweij, J. Schornagel, P. D. De Mulder, 1992, Head & neck.

Quality assurance in clinical trials.

P. Therasse, J. Bernier, R. Grol, 2003, Critical reviews in oncology/hematology.

The chemotherapy of head and neck cancer.

P. D. De Mulder, 1999, Anti-cancer drugs.

Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma.

P. D. De Mulder, V. Rutten, P. Steerenberg, 1993, Anticancer research.

Consensus regarding multiple day and rescue antiemetic therapy

M. Kris, F. Roila, P. D. De Mulder, 1998, Supportive Care in Cancer.

Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam.

J. Verweij, D. Cunningham, J. Smyth, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Repetitive weekly cycles of 4-day continuous infusion of recombinant interleukin-2: a phase I study.

P. D. De Mulder, G. Stoter, R. Jansen, 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Coincidence of seminoma and sarcoidosis: a myth or fact?

P. Pauwels, P. D. De Mulder, V. Tjan-Heijnen, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Intravenous magnesium supplementation during cisdiammine-dichloroplatinum administration prevents hypomagnesemia.

P. D. De Mulder, J. Willems, A. Theeuwes, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors.

C. Sternberg, A. V. van Oosterom, P. D. De Mulder, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Toxic dermatitis induced by 10‐ethyl‐10‐deazaaminopterin (10‐EdAM), a novel antifolate

J. Verweij, J. Schornagel, F. Cognetti, 1990, Cancer.

Treatment options in hormone resistant prostate cancer.

C. Sternberg, J. Schalken, P. D. De Mulder, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Possibilities for transborder cooperation in breast cancer care in Europe: a comparative analysis regarding the content, quality and evidence use of breast cancer guidelines.

R. Grol, P. D. De Mulder, H. Wollersheim, 2008, Breast.

Optimal control of acute cisplatin-induced emesis.

J. Verweij, P. D. De Mulder, R. de Wit, 1996, Oncology.

Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma.

P. van den Broek, J. Verweij, J. Schornagel, 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Commonly used imaging techniques for diagnosis and staging.

W. Oyen, M. Oudkerk, R. Reznek, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alpha and gamma interferon in the treatment of advanced renal cell carcinoma.

F. Debruyne, P. D. De Mulder, S. Strijk, 1988, Seminars in surgical oncology.

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948)

L Collette, L. Collette, S. Fosså, 2005, British Journal of Cancer.

Soft tissue sarcoma and hypercalcemia.

P. D. De Mulder, G. Vreugdenhil, Q. V. van Hoesel, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma.

J. Witjes, P. D. De Mulder, G. Oosterhof, 1997, European urology.

Induction Chemotherapy with Cisplatin and Continuous Infusion 5‐Fluorouracil in Locally Far‐Advanced Head and Neck Cancer

G. Snow, J. Verweij, J. Schornagel, 1989, American Journal of Clinical Oncology.

Interleukin-12 has no effect on vascular density, perfusion, hypoxia and proliferation of an implanted human squamous cell carcinoma xenograft tumour despite up-regulation of ICAM-1.

J. Bussink, P. D. de Wilde, A. J. van der Kogel, 2005, Anticancer research.

Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract.

L. Collette, C. Sternberg, P. D. De Mulder, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

M. Piccart, J. Wanders, J. Verweij, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

The quality of chemotherapy and its quality assurance.

P. D. De Mulder, P. Ottevanger, 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

New prospects in the management of metastatic renal cell carcinoma. Experimental and clinical data.

J. Schalken, F. Debruyne, P. D. De Mulder, 1990, Progress in clinical and biological research.

Interferon‐α‐2a with or without 13‐cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma

M. van Glabbeke, S. Fosså, M. Fey, 2004 .

Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma.

M. van Glabbeke, S. Fosså, M. Fey, 2004, Cancer.

Leptomeningeal carcinomatosis in relapsed non-seminoma testis: a 1-year complete remission with high-dose chemotherapy.

D. V. van Spronsen, P. D. De Mulder, T. Smilde, 2005, Anti-Cancer Drugs.

Long-term follow up of breast cancer patients treated for hypercalcaemia with aminohydroxypropylidene bisphosphonate (APD)

P. D. De Mulder, J. Grutters, A. Hermus, 2004, Breast Cancer Research and Treatment.

[The Dutch Health Council report on palliative chemotherapy: possible confusion on ideas].

J. Verweij, P. D. De Mulder, H. Pinedo, 2004, Nederlands tijdschrift voor geneeskunde.

EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors.

R. Paridaens, A. V. van Oosterom, P. D. De Mulder, 1997, European journal of cancer.

Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma.

S. Kaye, P. D. De Mulder, W. W. ten Bokkel Huinink, 1990, Journal of biological response modifiers.

5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron.

C. Seynaeve, J. Verweij, P. D. De Mulder, 1991, Anti-cancer drugs.